
Sign up to save your podcasts
Or


Cognitive change is one of the most common—and most misunderstood—symptoms of multiple sclerosis. In this episode, host Brett Drummond is joined by Dr. Vicki Levitt (Columbia University) and Dr. Tom Fuchs (MS Center Amsterdam) to explore why cognition remains one of the biggest unmet challenges in MS care.
Although problems with memory, attention, information processing speed, and executive function affect many people with MS, cognitive symptoms are often overlooked in routine clinical practice. The conversation examines why current assessment tools are not widely used, the barriers to implementing cognitive screening in busy clinics, and why measuring cognitive change is becoming increasingly important as treatments continue to improve physical outcomes.
From practical challenges in the clinic to cutting-edge research shaping the future, this episode explores how better measurement, earlier detection, and more personalised approaches could help protect one of the outcomes that matters most to people living with multiple sclerosis.
--------------------------------
This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.
By The European Committee for Treatment and Research in Multiple Sclerosis4.5
22 ratings
Cognitive change is one of the most common—and most misunderstood—symptoms of multiple sclerosis. In this episode, host Brett Drummond is joined by Dr. Vicki Levitt (Columbia University) and Dr. Tom Fuchs (MS Center Amsterdam) to explore why cognition remains one of the biggest unmet challenges in MS care.
Although problems with memory, attention, information processing speed, and executive function affect many people with MS, cognitive symptoms are often overlooked in routine clinical practice. The conversation examines why current assessment tools are not widely used, the barriers to implementing cognitive screening in busy clinics, and why measuring cognitive change is becoming increasingly important as treatments continue to improve physical outcomes.
From practical challenges in the clinic to cutting-edge research shaping the future, this episode explores how better measurement, earlier detection, and more personalised approaches could help protect one of the outcomes that matters most to people living with multiple sclerosis.
--------------------------------
This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

298 Listeners

50 Listeners

28,099 Listeners

111,948 Listeners

151 Listeners

871 Listeners

51 Listeners

5,201 Listeners

6,089 Listeners

127 Listeners

2,040 Listeners

84 Listeners